Arch-backed biotech hauls in a fast B round as its reborn anti-psychotic zooms to a PhII finish line
Steve Paul has booked a $68 million clinical round for his single asset anti-psychotic biotech now in a Phase II study for schizophrenia. And with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
